InvestorsHub Logo
Followers 67
Posts 3828
Boards Moderated 0
Alias Born 11/23/2014

Re: None

Wednesday, 07/20/2016 3:36:28 PM

Wednesday, July 20, 2016 3:36:28 PM

Post# of 210
Recent Highlights

The company is also pleased to announce that it has completed enrollment of its Phase 1b/2 clinical trial testing Resolaris in patients with limb-girdle muscular dystrophy 2B (LGMD2B or dysferlinopathies) or facioscapulohumeral muscular dystrophy (FSHD). Data from this clinical trial is expected to be announced in the fourth quarter of this year.


http://atyrpharma.investorroom.com/2016-05-11-aTyr-Pharma-Announces-First-Quarter-2016-Operating-Results

Everything is in my own opinion. Do what you think is right.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LIFE News